Radi by sme, aby ste sa stali súčasťou našej komunity. Pripojte sa k nášmu Discordu pre spojenie s nami a ostatnými členmi!

Ticker
COLO-B.CO

Price
797.20
Stock movement up
+6.80 (0.86%)
Company name
Coloplast A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Instruments & Supplies
Trhová kapitalizácia
165.29B
Hodnota ent
194.63B
Cena/Predaje
6.12
Cena/Účtovná hodnota
9.21
Výnos dividend
-
Rast dividend
-
Roky rastu
-
Výplata FCF
320.65%
Koncové P/E
32.72
Vyprojektované P/E
29.24
PEG
-
Rast EPS
4.33%
1 ročná návratnosť
4.26%
3 ročná návratnosť
-9.92%
5 ročná návratnosť
0.53%
10 ročná návratnosť
4.44%
Naposledy aktualizované: 2024-12-21

DIVIDENDY

COLO-B.CO nevypláca dividendy alebo neboli prijaté žiadne údaje

VALUÁCIE

Pomery valuácie

Loading...
Údaje o pomeroch valuácie
Koncové P/E32.72
Cena k OCF59.76
Cena k FCF112.29
Cena k EBITDA37.96
EV k EBITDA44.70

Ocenenie (predaj/účtovná hodnota)

Loading...
Údaje o valuácii (predaj/účtovná hodnota).
Cena k Predajom6.12
Cena k účtovnej hodnote9.21
EV k Predajom7.20

FINANCIE

Na akciu

Loading...
Údaje na zdieľanie
Aktuálny počet akcií207.34M
EPS (TTM)22.45
FCF na akciu (TTM)6.54

Výkaz ziskov a strát

Loading...
Údaje výkazu ziskov a strát
Výnosy (TTM)27.03B
Hrubý zisk (TTM)18.27B
Prevádzkový príjem (TTM)7.37B
Čistý príjem (TTM)5.05B
EPS (TTM)22.45
EPS (1 rok dopredu)27.26

Marža

Loading...
Údaje o marži
Hrubá marža (TTM)67.59%
Prevádzková marža (TTM)27.25%
Zisková marža (TTM)18.69%

Súvaha

Loading...
Ak chcete získať prístup k tomuto grafu, vytvorte si prosím bezplatný účet alebo sa prihláste
Údaje o Súvahe
Hotovosť788.00M
Čisté pohľadávky4.67B
Celkové aktíva10.44B
Goodwill19.38B
Nehmotný majetok10.96B
Nehnuteľnosti, stroje a zariadenia13.27B
Celkové aktíva48.07B
Splatné účty1.52B
Krátkodobý/Aktuálny dlhodobý dlh22.63B
Krátkodobé záväzky celkom10.20B
Celkové záväzky30.13B
Imanie vlastníkov akcií17.94B
Čistý hmotný majetok0.00

Peňažný tok

Loading...
Ak chcete získať prístup k tomuto grafu, vytvorte si prosím bezplatný účet alebo sa prihláste
Údaje o peňažnom toku
Prevádzkový peňažný tok (TTM)2.77B
Kapitálové výdavky (TTM)1.29B
Voľný peňažný tok (TTM)1.47B
Vyplatené dividendy (TTM)4.72B

Finančné výnosy

Loading...
Ak chcete získať prístup k tomuto grafu, vytvorte si prosím bezplatný účet alebo sa prihláste
Údaje o finančných výnosoch
Rentabilita kapitálu28.16%
Návratnosť aktív10.51%
Návratnosť investovaného kapitálu12.60%
Hotovostná návratnosť investovaného kapitálu3.67%

INFORMÁCIE O AKCIÁCH

Akciové grafy

Loading...
Údaje o cene akcií
Otvoriť791.60
Denné maximum799.20
Denné minimum786.60
Denný objem333K
Historické maximum1182.50
1 ročný odhad analytikov926.10
Beta0.34
EPS (TTM)22.45
Dividenda na akciu-
Dátum ex-div6 Dec 2024
Ďalší dátum zárobkov4 Feb 2025

Potenciál poklesu ceny

Loading...
Údaje o potenciáli poklesu ceny
COLO-B.COS&P500
Aktuálny pokles ceny proti historickému maximu-32.58%-2.74%
Najvyšší pokles ceny-43.67%-56.47%
Dátum najvyššieho poklesu28 Oct 19949 Mar 2009
Priemerný pokles z maxima-11.73%-11.13%
Priemerný čas k novému maximumu16 days12 days
Maximálny čas k novému maximumu854 days1805 days
PODROBNOSTI O SPOLOČNOSTI
COLO-B.CO (Coloplast A/S) company logo
Trhová kapitalizácia
165.29B
Kategória trhovej kapitalizácie
Large-cap
Popis
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Zamestnanci
16639
Vzťahy s investormi
-
CEO
Krajina
Denmark
Mesto
Typ akcie
-
CCC status
-
Dividendová frekvencia
-
PODUJATIA A PREZENTÁCIE
UdalostiPrezentácie
Loading...
POROZUMIEŤ PODNIKU
Loading...
NOVINKY O SPOLOČNOSTI
Všetky novinkyTlačové správy
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of ye...
5. decembra 2024
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted t...
4. decembra 2024
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based produc...
14. novembra 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk...
12. novembra 2024
Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.
6. novembra 2024
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates b...
5. novembra 2024
2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraord...
5. novembra 2024
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of...
5. novembra 2024
Earnings preview of key companies reporting this week and what to look out for.
1. novembra 2024
Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial...
21. októbra 2024
Ďalšia strana